Aldolase predicts subsequent myopathy occurrence in systemic sclerosis

Area of Science:

• Rheumatology
• Neuromuscular Diseases
• Biomarker Discovery

Background:

• Myopathy related to systemic sclerosis (Myo-SSc) is a significant complication.
• Predicting Myo-SSc is crucial for timely intervention.
• Existing biomarkers for Myo-SSc prediction require further evaluation.

Purpose of the Study:

• To assess the predictive value of serum biomarkers for developing Myo-SSc.
• To compare the efficacy of aldolase, CK, ALT, AST, and CRP in predicting Myo-SSc.
• To identify reliable indicators for early Myo-SSc risk stratification.

Main Methods:

• Prospective monocentric study of 137 SSc patients over four years.
• Longitudinal monitoring for Myo-SSc development using European NeuroMuscular Centre criteria.
• Analysis of baseline serum aldolase, CK, ALT, AST, and CRP levels for predictive performance.

Main Results:

• Plasma aldolase demonstrated the highest predictive value (ROC AUC 0.80) for Myo-SSc occurrence.
• Aldolase levels > 9 U/L significantly increased Myo-SSc risk (HR 10.3).
• CK and ALT showed moderate predictive value, while AST and CRP were not predictive.

Conclusions:

• Increased plasma aldolase is an accurate predictor of subsequent Myo-SSc in SSc patients.
• This finding can guide early treatment initiation for potentially reversible muscle damage.
• Aldolase serves as a valuable biomarker for Myo-SSc risk assessment.